Mantle Cell Lymphoma
News
Bortezomib plus vorinostat shows modest response in MCL
The phase 2 trial looked at the combination in mantle cell lymphoma and diffuse large B-cell lymphoma patients.
News
British good practice paper offers MCL diagnosis pearls
The good practice paper includes new information on pathology and use of PET/CT scanning in staging of disease.
News
Overcoming TP53 mutation proves difficult in MCL
A new study shows disappointing results for the addition of lenalidomide to chemoimmunotherapy regimens.
News
Adding bortezomib does not improve MCL outcomes
The addition of bortezomib is a bust in patients with newly diagnosed mantle cell lymphoma.
News
In young MCL patients, optimal treatment may vary
Novel agents have produced mixed results in younger mantle cell lymphoma patients.
News
PDPK1 could be novel target in MCL
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.
News
Ibrutinib plus venetoclax is active in mantle cell lymphoma
The combination appears to outperform the single agents when treating relapsed/refractory mantle cell lymphoma.
News
Time to rethink MCL treatment, trial design
Dr. Leonid Yavorkovsky of Kaiser Permanente San Jose Medical Center questions the traditional approach to treatment of class mantle cell lymphoma...
Conference Coverage
Outpatient CAR T infusions feasible using liso-cel
SALT LAKE CITY – Though most patients are admitted later, hospital stays are shorter with outpatient CAR T infusion.
News
Ibrutinib linked to invasive fungal infections
The researchers called for greater awareness of the potential for fungal infection in ibrutinib-treated patients.